Email ID
Password
Scrip   
Ception and Cephalon stumble on mixed Cinquil data
24 November 2009
Asher Mullard

A Phase IIb/III study of Ception Therapeutics' Cinquil (reslizumab) for the treatment of paediatric eosinophilic oesophagitis (EOE) has yielded mixed results, hitting only one of two co-primary endpoints. Cephalon, which holds an option to acquire privately-owned Ception, saw its share price fall...



Please Login to read the full article.
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36